Personalised Dosing – Patient-centered Dupilumab Dosing Regimen in AD

In this MEDtalk, MD, and Ph.D., Lotte S. Spekhorst presents her study presented at this year’s EADV, investigating different dupilumab dosing regimens in patients with controlled atopic dermatitis (AD). Results suggest a successful dose reduction regimen related to the serum drug levels and serum biomarkers. See original publication here.